Market Place
Sourcing Support
All News #Library
Biotech
Brainstorm Cell Therapeutics Reveals 2025 Financials, Updates
01 Apr 2026 //
PR NEWSWIRE
Brainstorm Cell Therapeutics Reveals Q3 2025 Financials Update
15 Nov 2025 //
PR NEWSWIRE
BrainStorm to Report Q2 Financial Results and Corporate Update
08 Aug 2025 //
PR NEWSWIRE
ALS Advocates Urge FDA Review of BrainStorm NurOwn Data
08 Jul 2025 //
BIOSPACE
BrainStorm Partners with Minaris for NurOwn Phase 3b ALS trials
28 May 2025 //
PR NEWSWIRE
BrainStorm`s NurOwn® Data Chosen for ISCT 2025 Presentation
29 Apr 2025 //
PR NEWSWIRE
BrainStorm Cell Submits FDA IND Amendment for NurOwn in ALS
10 Apr 2025 //
PR NEWSWIRE
BrainStorm Issues 2024 Letter to Shareholders
30 Dec 2024 //
PR NEWSWIRE
BrainStorm Secures U.S. Patent for Exosome Platform Technology
03 Dec 2024 //
PR NEWSWIRE
BrainStorm Cell Presents Positive NurOwn® Survival Data at NEALS
28 Oct 2024 //
PR NEWSWIRE
BrainStorm Provides Update On Phase 3b NurOwn Trial At Summit
07 Oct 2024 //
PR NEWSWIRE
BrainStorm Cell Therapeutics to Present on NurOwn® at NEALS Meeting
24 Sep 2024 //
PR NEWSWIRE
BrainStorm Cell Therapeutics Publishes NurOwn`s® Biomarker Data
10 Apr 2024 //
PR NEWSWIRE
BrainStorm Cell Submits SPA Request to FDA for Phase 3b Trial of NurOwn
23 Feb 2024 //
PR NEWSWIRE
BrainStorm Granted Patents for Allogeneic Exosome Platform-Product
26 Dec 2023 //
PR NEWSWIRE
BrainStorm to Meet with FDA to Discuss Development Plan for NurOwn
18 Oct 2023 //
PR NEWSWIRE
BrainStorm Cell Data Show Treatment with NurOwn Significantly Reduces NfL
07 Jul 2023 //
PR NEWSWIRE
BrainStorm Announces FDA Committee Meeting to Review NurOwn BLA Scheduled
06 Jun 2023 //
PR NEWSWIRE
BrainStorm Announces FDA Advisory Committee Meeting to Review BLA for NurOwn
27 Mar 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.